ReviewNature reviews. Drug discovery2026
Induced proximity-based therapeutic modalities.
Review in Nature reviews. Drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Bridging E3 Ligase Binding and Targeted Degradation Through Fluorescence Polarization.International journal of molecular sciences · 2026Article
- Nucleoporins in Cancer: Functional Roles and Therapeutic Opportunities.Cancer discovery · 2026Article
- Broadening the molecular glue landscape.Nature chemical biology · 2026Article
- Induced proximity-based therapeutics for advanced prostate cancer.npj drug discovery · 2026Review
- Linkerability of Protein Ligands: Insights From Cocrystal Structures and Implications for DNA-Encoded Libraries.Molecular informatics · 2026Article
- Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition.bioRxiv : the preprint server for biology · 2026Article
- Targeted Transcriptional Repression by Induced Proximity.ACS central science · 2026Article
- Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues.Science (New York, N.Y.) · 2026Article
- Article
- Tagging the Tank: Ubiquitin-mediated clearance of cellular energy reserves.Cell research · 2026Article
- Marked for destruction.Nature biotechnology · 2026Article
- Turning KEAP1 against NRF2.Nature chemical biology · 2026Article
- Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications.ACS pharmacology & translational science · 2026Review
- Review
- An Optimized RNF126-Targeting Covalent Handle for Molecular Glue Degraders.bioRxiv : the preprint server for biology · 2026Article
- Mitophagy-driven multidimensional regulation of tumor immune evasion and context-dependent therapeutic strategies.Journal of translational medicine · 2026Review
- From Serendipity to Strategy: Rationalizing Molecular Glue Discovery and Proximity-Induced Pharmacology through Chemical Biology.Journal of the American Chemical Society · 2026Review
- Molecular diversity turns 30.Molecular diversity · 2026Article
- Therapeutic inhibition of RAS in non-small cell lung cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Proximity is a key component of nearly all regulatory pathways within biological systems. Over the past few decades, the rapid development of induced proximity modalities has allowed for therapeutic intervention beyond classical occupancy-driven pharmacology. These modalities comprise multispecific small molecules or biologic agents that co-opt native biological pathways by inducing an interaction between biomolecules. Small-molecule 'molecular glues' modify protein surfaces to induce non-native interactions or to stabilize existing protein-protein interactions. They have been in the clinic since the 1980s but have more recently been shown to enable targeted protein degradation or inhibition and have been rationally designed to achieve this. Early discoveries on molecular glues spearheaded the development of next-generation heterobifunctional modalities for targeted protein degradation, such as proteolysis-targeting chimeras, which are seeing early-stage clinical success. Here, we aim to survey the field of induced proximity with a focus on potential therapeutic applications. We discuss the emergence of novel approaches to control cellular processes beyond protein degradation, including post-translational modifications, cellular localization and transcriptional activation. Some of these approaches are showing preclinical efficacy in various disease models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.